T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...
GlobalData on MSN
BMS and Microsoft partner for AI-based lung cancer detection
The partnership aims to deploy AI capabilities that automatically analyse X-ray and CT images to assist radiologists.
GlobalData on MSN
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM
The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.
Harald Hampel is recognized as an influential leader in neuroscience, and will bring expertise in Alzheimer's disease to BMS.
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Clinical Trials Arena on MSN
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff
BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.
This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the upcoming patent cliff.
The "Electric Vehicle Battery Management System - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. The Electric ...
BMS, an independent insurance and reinsurance broker, has announced the appointment of James Pearce as a Senior Broker, Cyber ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results